Skip to content

Clinical trials

Phase 3 Tuberculosis, Pulmonary trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Tuberculosis, Pulmonary Phase: Phase 3 Clear all

35 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20072
20083
20092
20101
20141
20151
20161
20172
20191
20203
20211
20222
20231
20244
20255
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Recruiting7
Not yet recruiting5
Unknown status3
Active, not recruiting2
Terminated1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Global Alliance for TB Drug Development3
Ministry of Science and Technology, India3
Beijing Chest Hospital2
Institute of Tropical Medicine, Belgium2
Kaohsiung Veterans General Hospital.2
Médecins Sans Frontières, France2
National Institute of Allergy and Infectious Diseases (NIAID)2
Shenzhen Third People's Hospital2
Tuberculosis Research Centre, India2
Barts & The London NHS Trust1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Tuberculosis, Pulmonary35
Tuberculosis15
Tuberculosis, Multidrug-Resistant8
Extensively Drug-Resistant Tuberculosis3
HIV Infections3
Bacterial Infections2
Mycobacterium Infections2
AIDS-Related Opportunistic Infections1
Acquired Immunodeficiency Syndrome1
Gram-Positive Bacterial Infections1

Trials

Showing 26 to 35 of 35. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.